Just starting a fun thread! (posted also in the RAD thread).
I was thinking about investing in a promising Paul Hopper Biotech.
RAD and CHM have similar market caps, are in the cancer space, with multiple IP opportunities, similar cash burn with similar cash on hand and at a similar age in its corporate evolution. If you had to choose only one investment, which would it be and why?
Paul Hopper IP opportunists CHM VS RAD
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable